Bladder Cancer Clinical Trials: 895 Active Trials, 157 Changes This Month

86 trials changed in the last 30 days: 2 stopped, 39 with notable changes, 45 with minor changes only.

Stopped

BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

Trial terminated

Sponsor's reason: The decision is based only on the Sponsor's internal portfolio prioritization and resource management considerations and is not due to the investigational product's toxicity considerations.

Also in this update: Final enrollment: 3 participants — 3% of the 120 planned; Primary completion date changed from estimate of Sep 1, 2027 to Jan 30, 2026

SystImmune Inc.Phase 1 NCT06714617 Registry history of NCT06714617 on ClinicalTrials.gov (opens the registry)

Updated Sep 22, 2026
Stopped

Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy

Trial status changed: Recruiting → Withdrawn

Sponsor's reason: PI left institution

Case Comprehensive Cancer CenterPhase 2 NCT06290687 Registry history of NCT06290687 on ClinicalTrials.gov (opens the registry)

Updated Sep 24, 2026
Notable

Cabozantinib S-malate and Nivolumab With or Without Ipilimumab · Metastatic Genitourinary Tumors

Primary and study completion pushed from Sep 30, 2026 to Jul 30, 2027

National Cancer Institute (NCI)Phase 1 NCT02496208 Registry history of NCT02496208 on ClinicalTrials.gov (opens the registry)

Updated Oct 15, 2026
Notable

uTRACT · Jelmyto Registry: A Registry · Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

Primary completion pushed from Apr 2026 to Oct 2027

Also in this update: Primary endpoint(s) modified; Enrollment increased: 400 → 450 participants

UroGen Pharma Ltd.Not specified NCT05874921 Registry history of NCT05874921 on ClinicalTrials.gov (opens the registry)

Updated Sep 29, 2026
Notable

LOBSTER · Longitudinal Bladder Cancer Study for Tumour Recurrence

Primary completion pushed from May 30, 2026 to Oct 2027

Also in this update: Enrollment closed, study ongoing; Study completion pushed from Aug 31, 2026 to Jan 31, 2028

Pacific Edge LimitedNot specified NCT05080998 Registry history of NCT05080998 on ClinicalTrials.gov (opens the registry)

Updated Sep 17, 2026
Notable

Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects

Primary completion pushed from Oct 3, 2026 to Oct 3, 2027

Also in this update: Study completion pushed from Apr 3, 2027 to Apr 3, 2028

Zhujiang HospitalPhase 2 NCT04861584 Registry history of NCT04861584 on ClinicalTrials.gov (opens the registry)

Updated Oct 9, 2026
Notable

RC48 Combined With Toripalimab as Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients

Primary completion pushed from May 1, 2026 to May 1, 2028

Also in this update: Study completion pushed from May 1, 2027 to May 1, 2029

Zhujiang HospitalPhase 1/2 NCT06341400 Registry history of NCT06341400 on ClinicalTrials.gov (opens the registry)

Updated Oct 8, 2026
Notable

In-home Intravesical Chemotherapy · Bladder Cancer, INVITE Trial

Primary completion pushed from Dec 31, 2026 to Dec 31, 2027

Also in this update: Study completion pushed from Dec 31, 2026 to Dec 31, 2028

Mayo ClinicPhase 1/2 NCT06704191 Registry history of NCT06704191 on ClinicalTrials.gov (opens the registry)

Updated Oct 8, 2026
Notable

NAUTICAL · Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL)

Primary completion pushed from Dec 2026 to Dec 2027

Also in this update: Study completion pushed from Dec 2027 to Dec 2028

University Health Network, TorontoPhase 3 NCT04574960 Registry history of NCT04574960 on ClinicalTrials.gov (opens the registry)

Updated Oct 6, 2026
Notable

Targeted Therapy Directed by Genetic Testing · Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Primary and study completion pushed from Dec 31, 2026 to Dec 31, 2027

National Cancer Institute (NCI)Phase 2 NCT02465060 Registry history of NCT02465060 on ClinicalTrials.gov (opens the registry)

Updated Sep 29, 2026
Notable

Detaenial Sigmoid Neobladder and Ileal Neobladder

Primary completion pushed from Aug 30, 2025 to Aug 30, 2027

Also in this update: Trial status changed: Unknown → Recruiting; Study completion pushed from Sep 30, 2025 to Sep 30, 2028

Zhujiang HospitalNot applicable NCT03108196 Registry history of NCT03108196 on ClinicalTrials.gov (opens the registry)

Updated Oct 9, 2026
Notable

Capsule Sparing Cystectomy and Radical Cystoprostatectomy · Bladder Cancer

Primary completion pushed from Dec 1, 2025 to Dec 1, 2028

Also in this update: Study completion pushed from Dec 1, 2026 to Jul 1, 2029

Zhujiang HospitalNot applicable NCT05067101 Registry history of NCT05067101 on ClinicalTrials.gov (opens the registry)

Updated Oct 9, 2026
Notable

Supraspinal Control of Lower Urinary Tract Function · Orthotopic Sigmoid Neobladder

Primary completion pushed from Jan 1, 2025 to Dec 1, 2028

Also in this update: Trial status changed: Unknown → Recruiting; Study completion pushed from Jun 1, 2025 to Jun 1, 2029; and 1 more change in the last 30 days

Zhujiang HospitalNot specified NCT05558111 Registry history of NCT05558111 on ClinicalTrials.gov (opens the registry)

Updated Oct 8, 2026
Notable

HTL0039732 · Advanced Solid Tumours

Primary and study completion pushed from Jun 2027 to Dec 31, 2028

Also in this update: Interventions modified

Cancer Research UKPhase 1/2 NCT05944237 Registry history of NCT05944237 on ClinicalTrials.gov (opens the registry)

Updated Oct 1, 2026
Notable

Futibatinib in Combination With Durvalumab Prior to Cystectomy · Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy

Primary and study completion pushed from Dec 31, 2026 to Jul 31, 2027

Yuanquan YangPhase 2 NCT06263153 Registry history of NCT06263153 on ClinicalTrials.gov (opens the registry)

Updated Oct 1, 2026
Notable

Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer

Primary completion pushed from May 2026 to May 2027

Fox Chase Cancer CenterPhase 2 NCT04506554 Registry history of NCT04506554 on ClinicalTrials.gov (opens the registry)

Updated Sep 21, 2026
Notable

POLO · Precise Chemoresection in Low-grade NMIBC Using Drug Screens in Patient-derived Organoids

Primary completion pushed from Oct 2026 to Nov 30, 2030

Also in this update: Sponsor changed: University of Bern to Hospital Centre Biel/Bienne; Study completion pushed from Oct 2029 to Nov 30, 2031

Hospital Centre Biel/BiennePhase 2 NCT06227065 Registry history of NCT06227065 on ClinicalTrials.gov (opens the registry)

Updated Sep 18, 2026
Notable

STAR-EV · Enfortumab Vedotin and Stereotactic Radiation for Localized Bladder Cancer

Primary completion pushed from Jul 1, 2026 to Sep 30, 2028

Also in this update: Study completion pushed from Jul 1, 2027 to Sep 30, 2029

University of Texas Southwestern Medical CenterPhase 1/2 NCT06394570 Registry history of NCT06394570 on ClinicalTrials.gov (opens the registry)

Updated Sep 17, 2026
Notable

BCG at Home · Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support

Primary completion pushed from Aug 5, 2026 to Feb 5, 2027

Also in this update: Study completion pushed from Sep 5, 2026 to Apr 5, 2027

Abramson Cancer Center at Penn MedicineNot applicable NCT07048496 Registry history of NCT07048496 on ClinicalTrials.gov (opens the registry)

Updated Oct 5, 2026
Notable

Perioperative Durvalumab With Neoadjuvant ddMVAC · Muscle-Invasive Bladder Cancer (NIAGARA-2)

Primary endpoint(s) modified

Also in this update: Phase changed: Phase 3 → Phase 2; Primary and study completion moved earlier from Oct 31, 2028 to Aug 30, 2028

AstraZenecaPhase 2 NCT06960577 Registry history of NCT06960577 on ClinicalTrials.gov (opens the registry)

Updated Oct 8, 2026

Show 45 trials with minor changes only

Minor

PARADIGM-1 · 1/1b Study of ZH9 Treatment · Non-Muscle Invasive Bladder Cancer

Trial completed

Also in this update: Study completion date changed from estimate of Jul 30, 2027 to Aug 5, 2026

Prokarium LtdPhase 1 NCT06181266 Registry history of NCT06181266 on ClinicalTrials.gov (opens the registry)

Updated Oct 14, 2026
Minor

TRK-950 in Combinations With Anti-Cancer Treatment Regimens · Advanced Solid Tumors

Trial completed

Toray Industries, IncPhase 1 NCT03872947 Registry history of NCT03872947 on ClinicalTrials.gov (opens the registry)

Updated Oct 8, 2026
Minor

ABILITY-1 · Beta-only IL-2 ImmunoTherapY Study

Primary completion pushed from Jun 30, 2026 to Nov 30, 2026

Also in this update: Enrollment increased: 115 → 160 participants; Study completion pushed from Dec 30, 2026 to Dec 30, 2028

Medicenna Therapeutics, Inc.Phase 1/2 NCT05086692 Registry history of NCT05086692 on ClinicalTrials.gov (opens the registry)

Updated Oct 13, 2026
Minor

Enfortumab Vedotin and Pembrolizumab · Bladder Cancer

Enrollment closed, study ongoing

Also in this update: Final enrollment: 27 participants (planned 23)

Memorial Sloan Kettering Cancer CenterPhase 2 NCT05239624 Registry history of NCT05239624 on ClinicalTrials.gov (opens the registry)

Updated Oct 13, 2026
Minor

AVA6000 in Solid Tumours

Enrollment closed, study ongoing

Also in this update: Study completion pushed from Aug 15, 2026 to Aug 6, 2027; Primary completion date changed from estimate of Jun 15, 2026 to Aug 7, 2026

Avacta Life Sciences LtdPhase 1 NCT04969835 Registry history of NCT04969835 on ClinicalTrials.gov (opens the registry)

Updated Oct 2, 2026
Minor

RESOLVE · Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma

Trial completed

Also in this update: Primary completion date changed from estimate of Aug 2026 to Jan 26, 2026; Final enrollment: 7 participants (planned 9)

University of UtahPhase 1 NCT05154994 Registry history of NCT05154994 on ClinicalTrials.gov (opens the registry)

Updated Oct 14, 2026
Minor

microDRIVE · Detection and Risk Stratification in Veterans Presenting With Microscopic Hematuria

Enrollment closed, study ongoing

Also in this update: Primary completion pushed from May 31, 2026 to Sep 30, 2026; Study completion pushed from Jun 30, 2026 to Sep 30, 2026

Pacific Edge LimitedNot specified NCT05889195 Registry history of NCT05889195 on ClinicalTrials.gov (opens the registry)

Updated Sep 16, 2026
Minor

Bortezomib With Gemcitabine/Doxorubicin · Urothelial Cancer and Other Solid Tumors

Trial completed

Also in this update: Primary completion date changed from estimate of Sep 30, 2026 to Apr 14, 2026

M.D. Anderson Cancer CenterPhase 1 NCT00479128 Registry history of NCT00479128 on ClinicalTrials.gov (opens the registry)

Updated Oct 9, 2026
Minor

MDX2001 · Advanced Solid Tumors

Enrollment increased: 285 → 330 participants

ModeX Therapeutics, An OPKO Health CompanyPhase 1/2 NCT06239194 Registry history of NCT06239194 on ClinicalTrials.gov (opens the registry)

Updated Oct 15, 2026
Minor

Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder

Trial completed

NYU Langone HealthPhase 2 NCT02621151 Registry history of NCT02621151 on ClinicalTrials.gov (opens the registry)

Updated Sep 30, 2026
Minor

Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer

Trial completed

Also in this update: Primary completion date changed from estimate of Mar 2027 to Sep 22, 2026

Memorial Sloan Kettering Cancer CenterPhase 2 NCT03093922 Registry history of NCT03093922 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026
Minor

Office-Based Ureteroscopy Utilizing a Single Use Digital, Flexible Ureteroscope for Upper Tract Urothelial Carcinoma

Primary and study completion pushed from Aug 2027 to Dec 2027

University of Michigan Rogel Cancer CenterNot applicable NCT07630155 Registry history of NCT07630155 on ClinicalTrials.gov (opens the registry)

Updated Oct 15, 2026
Minor

Guiding Value of Urinary Tumor DNA Testing in Cystoscopy for High-Risk/Very High-Risk Non-Muscle-Invasive Bladder Cancer

Enrollment closed, study ongoing

Tianjin Medical University Second HospitalNot applicable NCT07180212 Registry history of NCT07180212 on ClinicalTrials.gov (opens the registry)

Updated Sep 28, 2026
Minor

In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

Primary and study completion pushed from Dec 31, 2026 to May 1, 2027

Mayo ClinicPhase 2 NCT06265285 Registry history of NCT06265285 on ClinicalTrials.gov (opens the registry)

Updated Oct 2, 2026
Minor

Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

Primary and study completion pushed from Dec 18, 2026 to May 15, 2027

Mayo ClinicPhase 2 NCT07285044 Registry history of NCT07285044 on ClinicalTrials.gov (opens the registry)

Updated Sep 30, 2026
Minor

FORAGER-2 · Vepugratinib (LY3866288) · Cancer in the Urinary Tract

Trial sites reduced: 284 → 276 locations

And 1 more change in the last 30 days

Eli Lilly and CompanyPhase 3 NCT07218380 Registry history of NCT07218380 on ClinicalTrials.gov (opens the registry)

Updated Oct 7, 2026
Minor

TroFuse-031 · Sacituzumab Tirumotecan (Sac-TMT, MK-2870) · Urothelial Cancer (MK-2870-031)

Trial sites expanded: 95 → 104 locations

And 1 more change in the last 30 days

Merck Sharp & Dohme LLCPhase 3 NCT07419295 Registry history of NCT07419295 on ClinicalTrials.gov (opens the registry)

Updated Oct 6, 2026
Minor

Symbiotic-GU-06 · PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

Trial sites expanded: 173 → 184 locations

And 1 more change in the last 30 days

PfizerPhase 1/2 NCT07421700 Registry history of NCT07421700 on ClinicalTrials.gov (opens the registry)

Updated Oct 8, 2026
Minor

DK222 Study at Hopkins

Primary and study completion pushed from Sep 1, 2027 to Jan 31, 2028

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPhase 1 NCT07140315 Registry history of NCT07140315 on ClinicalTrials.gov (opens the registry)

Updated Sep 29, 2026
Minor

Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) · Muscle Invasive Bladder Cancer (EV-309)

Trial sites expanded: 14 → 19 locations

Astellas Pharma Global Development, Inc.Phase 3 NCT07566156 Registry history of NCT07566156 on ClinicalTrials.gov (opens the registry)

Updated Sep 30, 2026
Minor

ABLE-22 · Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy · High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

Trial sites expanded: 76 → 80 locations

Ferring PharmaceuticalsPhase 3 NCT06545955 Registry history of NCT06545955 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026
Minor

ABLE-32 · Nadofaragene Firadenovec vs. Observation · Intermediate Risk Non-Muscle Invasive Bladder Cancer

Trial sites expanded: 107 → 110 locations

Ferring PharmaceuticalsPhase 3 NCT06510374 Registry history of NCT06510374 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026
Minor

SURF303 · 2A/B Efficacy and Safety of Dabogratinib · Low Grade Upper Tract Urothelial Carcinoma

Trial sites expanded: 26 → 32 locations

Tyra Biosciences, IncPhase 2 NCT07265947 Registry history of NCT07265947 on ClinicalTrials.gov (opens the registry)

Updated Oct 2, 2026
Minor

HER3-DXd · Locally Advanced or Metastatic Solid Tumors

Trial sites expanded: 91 → 94 locations

Daiichi SankyoPhase 2 NCT06172478 Registry history of NCT06172478 on ClinicalTrials.gov (opens the registry)

Updated Oct 1, 2026
Minor

Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps · Muscle-invasive Bladder Cancer Keep Their Bladder

Trial sites expanded: 33 → 48 locations

Astellas Pharma Global Development, Inc.Phase 2 NCT07475806 Registry history of NCT07475806 on ClinicalTrials.gov (opens the registry)

Updated Sep 24, 2026
Minor

IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

Trial sites expanded: 17 → 20 locations

IDEAYA BiosciencesPhase 1 NCT07277413 Registry history of NCT07277413 on ClinicalTrials.gov (opens the registry)

Updated Sep 18, 2026
Minor

Pan-tumor MRD Study

Trial sites expanded: 2 → 47 locations

Paradigm HealthNot specified NCT06605404 Registry history of NCT06605404 on ClinicalTrials.gov (opens the registry)

Updated Sep 24, 2026
Minor

Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Trial sites expanded: 142 → 145 locations

National Cancer Institute (NCI)Phase 2 NCT06770582 Registry history of NCT06770582 on ClinicalTrials.gov (opens the registry)

Updated Sep 30, 2026
Minor

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

Trial sites expanded: 165 → 177 locations

National Cancer Institute (NCI)Phase 2 NCT07061964 Registry history of NCT07061964 on ClinicalTrials.gov (opens the registry)

Updated Sep 24, 2026
Minor

MK-2870-001 · I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)

Study completion pushed from Dec 31, 2026 to Nov 30, 2027

Also in this update: Primary completion date changed from estimate of Dec 31, 2026 to Nov 30, 2025

Klus Pharma Inc.Phase 1/2 NCT04152499 Registry history of NCT04152499 on ClinicalTrials.gov (opens the registry)

Updated Oct 9, 2026
Minor

THOR · Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab · Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations

Study completion pushed from Dec 31, 2026 to Dec 31, 2027

Janssen Research & Development, LLCPhase 3 NCT03390504 Registry history of NCT03390504 on ClinicalTrials.gov (opens the registry)

Updated Sep 21, 2026
Minor

DEFEND · Distance-Based Exercise to Preserve Function and Prevent Disability

Trial sites expanded: 18 → 23 locations

Alliance for Clinical Trials in OncologyNot applicable NCT07059884 Registry history of NCT07059884 on ClinicalTrials.gov (opens the registry)

Updated Oct 2, 2026
Minor

SURF302 · TYRA-300 · FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

Interventions modified

Tyra Biosciences, IncPhase 2 NCT06995677 Registry history of NCT06995677 on ClinicalTrials.gov (opens the registry)

Updated Sep 29, 2026
Minor

BISCAY · Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer

Study completion pushed from Jan 30, 2026 to Nov 30, 2026

AstraZenecaPhase 1 NCT02546661 Registry history of NCT02546661 on ClinicalTrials.gov (opens the registry)

Updated Oct 1, 2026
Minor

STELLAR-002 · Zanzalintinib in Combination With Immuno-Oncology or Other Agents · Solid Tumors

Interventions modified

ExelixisPhase 1 NCT05176483 Registry history of NCT05176483 on ClinicalTrials.gov (opens the registry)

Updated Oct 1, 2026
Minor

ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ · MAGE-A4 Positive Tumors (SURPASS)

Primary completion date changed from estimate of Dec 23, 2026 to Apr 15, 2026

USWM CT, LLCPhase 1 NCT04044859 Registry history of NCT04044859 on ClinicalTrials.gov (opens the registry)

Updated Sep 23, 2026
Minor

Nova-sTAR · Real-World Use and Outcomes of TAR-200 · Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States

Study completion pushed from Oct 9, 2029 to Jun 28, 2030

Janssen Research & Development, LLCNot specified NCT07309445 Registry history of NCT07309445 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026
Minor

Personalized Cancer Vaccine (PCV) Strategy · Solid Tumors and Molecular Residual Disease

Interventions modified

Washington University School of MedicinePhase 1 NCT06529822 Registry history of NCT06529822 on ClinicalTrials.gov (opens the registry)

Updated Sep 21, 2026
Minor

LIAM Mc · Linking In With Advice and Supports for Men Impacted by Metastatic Cancer

Study completion pushed from Jun 2026 to Feb 2028

Also in this update: Primary completion date changed from estimate of Jun 2026 to Aug 30, 2025

University College CorkNot applicable NCT05946993 Registry history of NCT05946993 on ClinicalTrials.gov (opens the registry)

Updated Oct 1, 2026
Minor
6 trials marked Unknown by the registry's verification sweep
1. Minor
  
  Engagement Dynamics Among Individuals Impacted by Bladder Cancer
  
  Registry marked status Unknown (sponsor has not verified the record since Aug 2023); last known: Not Yet Recruiting
  
  Power Life Sciences Inc.Not specified NCT06009510 Registry history of NCT06009510 on ClinicalTrials.gov (opens the registry)
  
  Changed Oct 4, 2026
2. Minor
  
  CNN-BC · Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer
  
  Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
  
  Fondazione Policlinico Universitario Agostino Gemelli IRCCSPhase 2 NCT05203913 Registry history of NCT05203913 on ClinicalTrials.gov (opens the registry)
  
  Changed Oct 4, 2026
3. Minor
  
  iNDUCT · & Efficacy of Durvalumab+Neoadjuvant Chemotherapy for High-risk Urothelial Carcinoma of the Upper Urinary Tract
  
  Registry marked status Unknown (sponsor has not verified the record since May 2023); last known: Recruiting
  
  Centre Hospitalier Universitaire de NīmesPhase 2 NCT04617756 Registry history of NCT04617756 on ClinicalTrials.gov (opens the registry)
  
  Changed Oct 4, 2026
4. Minor
  
  INu-RC · Pre-operative Immuno-Nutrition in Radical Cystectomy
  
  Registry marked status Unknown (sponsor has not verified the record since Apr 2024); last known: Not Yet Recruiting
  
  Fondazione IRCCS Policlinico San Matteo di PaviaNot applicable NCT06355518 Registry history of NCT06355518 on ClinicalTrials.gov (opens the registry)
  
  Changed Oct 4, 2026
5. Minor
  
  SkinHealth · Skin Health and QoL in Pts Receiving Anti-PD1/PDL1/CTLA4 or CDK Inhibitors
  
  Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
  
  Fondazione Policlinico Universitario Agostino Gemelli IRCCSNot specified NCT05878964 Registry history of NCT05878964 on ClinicalTrials.gov (opens the registry)
  
  Changed Oct 4, 2026
6. Minor
  
  Infectious Complications After Cystectomy: A Prospective Observational Study
  
  Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
  
  Ludwig-Maximilians - University of MunichNot specified NCT05153694 Registry history of NCT05153694 on ClinicalTrials.gov (opens the registry)
  
  Changed Oct 4, 2026
Registry verification sweep

Changed Oct 4, 2026

Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.

First posted	Trial	Sponsor	Phase
2026-10-06	NCT07860398 Feasibility of Automatic, Laser-based Distance Control in Persons With Superficial…	Optheras AS new
2026-10-02	NCT07855926 Perioperative Systemic Therapies in Muscle-Invasive Bladder Cancer (GUARDIANS)	LMU Klinikum new
2026-09-11	NCT07815665 A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in…	Summit Therapeutics new	Phase 2/3
2026-09-08	NCT07808216 Toripalimab Combined With Intravesical Gemcitabine as Adjuvant Therapy for High-Risk…	Tianjin First Central Hospital new	Phase 2
2026-08-28	NCT07793318 TR115 in ARID1A-Mutated Advanced Solid Tumors	Tarapeutics Science Inc. new	Phase 2
2026-08-25	NCT07784387 A Study to Characterize High-Risk Non-Muscle-Invasive Bladder Cancer Participants in…	Janssen-Cilag Farmaceutica Ltda. new
2026-08-24	NCT07781852 Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and…	Lumina Pharmaceuticals Inc new	Early Phase 1
2026-08-24	NCT07781956 Home-Based Supportive Care Program for NMIBC Patients Receiving Intravesical Perfusion…	Nanjing First Hospital, Nanjing Medical University new
2026-08-24	NCT07782164 Irreversible Electroporation (IRE) for Treating Recurrent Pelvic Tumors (PELFIRE Study)	Amsterdam UMC, location VUmc new
2026-08-11	NCT07758881 Evaluating the Safety and Performance of the Eight Medical Hyperthermia System IV 1.0 for…	Eight Medical International BV new

NCT ID	Title	Sponsor	Status	Updated
Phase 4
NCT06764095	Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally…	Mayo Clinic	Recruiting	2026-10-01
NCT06862219	A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer	Astellas Pharma Global Development, Inc.	Recruiting	2026-08-21
NCT07474519	Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette…	Ohio State University Comprehensive Cancer Center	Recruiting	2026-03-16
NCT05962541	Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic…	University of Roma La Sapienza	Recruiting	2025-12-31
NCT06781879	Chemoablation Or Bladder Resection With Adjuvant Chemotherapy in Recurrent Non-Muscle…	Jakob Kristian Jakobsen	Recruiting	2025-10-03
NCT04532606	Impact of Remimazolam on Prognosis After Bladder Cancer Surgery	Peking University First Hospital	Recruiting	2025-07-30
NCT06820255	DDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial…	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	Recruiting	2025-02-11
NCT06709196	Clinical Trial Testing Whether Targeted Antibiotic Prophylaxis Can Reduce Infections…	Copenhagen University Hospital, Rigshospitalet	Recruiting	2025-01-09
NCT07876817	A Prospective, Multi-Center, Phase 4, Single Arm Study To Assess The Safety and…	AstraZeneca	Not Yet Recruiting	2026-10-15
NCT07768358	Tucatinib Continuation Study	Pfizer	Not Yet Recruiting	2026-08-28
NCT06548438	The Impact of PDD During TURB for NMIBC	A.O.U. Città della Salute e della Scienza	Not Yet Recruiting	2024-08-12
Phase 3
NCT07419295	A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer…	Merck Sharp & Dohme LLC	Recruiting	2026-10-13
NCT07869836	BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy…	SystImmune Inc.	Recruiting	2026-10-13
NCT06510374	Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk…	Ferring Pharmaceuticals	Recruiting	2026-10-07
NCT07218380	A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract	Eli Lilly and Company	Recruiting	2026-10-07
NCT04574960	Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL)	University Health Network, Toronto	Recruiting	2026-10-06
NCT07480356	Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of…	Protara Therapeutics	Recruiting	2026-10-06
NCT06524544	A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus…	National Cancer Institute (NCI)	Recruiting	2026-10-05
NCT07000084	Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone)…	Alliance for Clinical Trials in Oncology	Recruiting	2026-10-02
NCT07566156	Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy…	Astellas Pharma Global Development, Inc.	Recruiting	2026-09-30
NCT06919965	A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants…	Janssen Research & Development, LLC	Recruiting	2026-09-28
NCT07498907	Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing…	Peking University First Hospital	Recruiting	2026-09-28
NCT06319820	A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in…	Janssen Research & Development, LLC	Recruiting	2026-09-25
NCT06545955	A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With…	Ferring Pharmaceuticals	Recruiting	2026-09-25
NCT06703476	A Study of Surgical Techniques During Cystectomy	Memorial Sloan Kettering Cancer Center	Recruiting	2026-09-22

Early Phase 1		15
Phase 1		112
Phase 1/2		86
Phase 2		217
Phase 2/3		15
Phase 3		88
Phase 4		11

Bladder Cancer clinical trials

What changed in the last 30 days

New sponsor entrants, last 90 days sponsors with their first trial in this area

Active trials by phase

Active trials top 25 of 895

Top sponsors by active trials in this area

Narrower conditions